Michael R Wood, Meredith J Noetzel, Bruce J Melancon, Michael S Poslusney, Kellie D Nance, Miguel A Hurtado, Vincent B Luscombe, Rebecca L Weiner, Alice L Rodriguez, Atin Lamsal, Sichen Chang, Michael Bubser, Anna L Blobaum, Darren W Engers, Colleen M Niswender, Carrie K Jones, Nicholas J Brandon, Michael W Wood, Mark E Duggan, P Jeffrey Conn, Thomas M Bridges, Craig W Lindsley
Herein, we report the structure-activity relationships within a series of potent, selective, and orally bioavailable muscarinic acetylcholine receptor 4 (M4) positive allosteric modulators (PAMs). Compound 6c (VU0467485) possesses robust in vitro M4 PAM potency across species and in vivo efficacy in preclinical models of schizophrenia. Coupled with an attractive DMPK profile and suitable predicted human PK, 6c (VU0467485) was evaluated as a preclinical development candidate.
February 9, 2017: ACS Medicinal Chemistry Letters